Skip to main content
. 2022 Jun 10;63(8):2024–2036. doi: 10.1111/epi.17304

FIGURE 1.

FIGURE 1

Overall incidence of (A) treatment‐emergent adverse events (TEAEs) classified as psychiatric disorders and (B) TEAEs potentially associated with behavioral disorders by number of concomitant antiseizure medications (ASMs) and specific concomitant ASMs in patients on one concomitant ASM (patients received placebo or brivaracetam [BRV] in addition to a single concomitant ASM; safety set). CBZ, carbamazepine; LTG, lamotrigine; OXC, oxcarbazepine; VPA, valproate.